NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
Clinical Trials
23 trialsNCT01644591 2026-03-05
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03340129 2026-02-02
ABC-X
Melanoma Institute Australia
Phase 2 Recruiting
NCT05830058 2026-01-05
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
Phase 2 Recruiting
NCT03304639 2025-11-12
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02713269 2025-10-30
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03712904 2025-09-24
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Thomas Jefferson University
Phase 2 Terminated
NCT03898908 2025-05-21
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT01416831 2025-03-17
SBRT/IL-2
Providence Health & Services
Phase 2 Active not recruiting
NCT04899908 2024-10-24
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT02978404 2024-06-28
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Completed
NCT04074096 2024-06-03
BEPCOME-MB
UNICANCER
Phase 2 Active not recruiting
NCT00003308 2023-06-22
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02821182 2022-12-29
A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.
University Hospital, Ghent
Phase 2 Completed
NCT05077280 2022-12-06
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
California Pacific Medical Center Research Institute
Phase 2 Recruiting
NCT02097732 2021-05-12
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT04042506 2021-04-12
SBRT as a Vaccination for Metastatic Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT01970527 2020-02-13
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
University of Washington
Phase 2 Terminated
NCT01721603 2018-01-23
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
University of California, San Francisco
Phase 2 Terminated
NCT01973608 2016-10-31
MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma
EMD Serono
Phase 2 Terminated
NCT00587964 2016-02-22
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02662725 2016-01-25
IPI+RTS
University Hospital, Lille
Phase 2 Completed
NCT00003911 2013-01-31
S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases
SWOG Cancer Research Network
Phase 2 Terminated